Summary
The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the
intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a
core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis.
ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come.
intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a
core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis.
ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/777372 |
| Start date: | 01-07-2018 |
| End date: | 31-12-2023 |
| Total budget - Public funding: | 24 065 172,00 Euro - 12 000 000,00 Euro |
Cordis data
Original description
The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in theintensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a
core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis.
ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come.
Status
CLOSEDCall topic
IMI2-2016-10-06Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH (Coördinator)
-
| AXXAM SPA
-
| BAYER AKTIENGESELLSCHAFT (BAYER)
-
| BOEHRINGER INGELHEIM INTERNATIONALGMBH
-
| MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
-
| NOVARTIS PHARMA AG
-
| PFIZER LIMITED
-
| SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
-
| THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
-
| THE UNIVERSITY OF LIVERPOOL
-
| THE UNIVERSITY OF MANCHESTER
-
| UNIVERSITAT WIEN
-
| UNIVERSITEIT LEIDEN
-
| VIFOR (INTERNATIONAL) AG